Crossmark

Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution

Crossref DOI link: https://doi.org/10.1186/s13075-021-02671-z

Published Online: 2022-01-03

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Verstappen, M. http://orcid.org/0000-0002-7850-5063
van Steenbergen, H. W.

de Jong, P. H. P.

van der Helm-van Mil, A. H. M.
Funding

Funding for this research was provided by:

reumanederland

horizon 2020 (714312)
License Information

Text and Data Mining valid from 2022-01-03

Version of Record valid from 2022-01-03
More Information

Article History

Received: 24 June 2021

Accepted: 7 November 2021

First Online: 3 January 2022

Declarations

:

: “Commisie Medische Ethiek” of the Leiden University Medical Centre (B19.008).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below